Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 4Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Metastatic Solid Tumors 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Glioblastoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 42Etoposide 37Cisplatin 23Topotecan 22Nivolumab 17pembrolizumab 12atezolizumab 12Ipilimumab 10Paclitaxel 9durvalumab 8Irinotecan 8Radiosurgery 6Pemetrexed 6rovalpituzumab tesirine 5Magnetic Resonance Spectroscopy 5trioctyl phosphine oxide 4trilaciclib 4etoposide phosphate 4berzosertib 4Sunitinib 4Specimen Handling 4Platinum 4PM 01183 4Dexamethasone 4veliparib 3tremelimumab 3olaparib 3carfilzomib 3cabozantinib 3Temozolomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Small Cell Lung Carcinoma × sacituzumab govitecan × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡